Table 2.
Efficacy variables (with 95% confidence intervals) at baseline, 5 months and 4 years’ follow-up
| Baseline | 5 months | 4 years | |
|---|---|---|---|
| Headache days/month (n = 50) | 25.0 (23.2–26.7) | 21.6 (18.9–24.4)* | 18.4 (15.1–21.8)*** |
| Days with acute headache drugs/month (n = 50) | 22.9 (21.0–24.8) | 13.3 (10.4–16.3)*** | 13.4 (10.3–16.4)*** |
| Headache hours/month (n = 50) | 8.1 (6.8–9.4) | 8.3 (7.1–9.6) | 7.7 (6.2–9.2) |
| Headache index/month (n = 50) | 449 (349–548) | 420 (306–534) | 320 (224–418)*** |
| Days with sick leave/month (n = 35) | 6.3 (1.7–11.0) | 2.2 (0.3–4.2)* | 0.9 (0.2–1.6)** |
| Mental health component (MCS-12) (n = 38) | 51.2 (44.6–57.7) | 57.9 (50.8–64.9)** | 62.7 (53.8–71.6)** |
| Physical health component (PCS-12) (n = 38) | 46.7 (40–53.1) | 51.0 (43.5–58.5)* | 59.8 (51.0–68.6)** |
| Number of prophylactic drugs tried, mean (n = 50) | 1.2 (0.8–1.6) | 1.9 (1.4–2.3)*** | 2.5 (2.0–3.0)*** |
*** p ≤ 0.001; ** p ≤ 0.01; * p < 0.05